再鼎醫藥(09688.HK)夥微醫建立泛腫瘤數字醫療服務平台
再鼎醫藥(09688.HK)(ZLAB.US)公布,於昨日(27日)與數字醫療健康平台微醫簽署戰略合作協議,雙方將通過整合資源,建立線上線下一體化醫療健康服務平台,並共同探索腫瘤疾病領域新型合作模式。
根據戰略協議,再鼎醫藥與微醫將建立以患者為中心的線上線下一體化醫療健康服務平台,優先從腫瘤疾病領域開始,探索開發先進的專病垂直領域的管理模式。雙方並將共同打造泛腫瘤患者的線上診療一體化平台,通過線上線下相結合,建立廣泛覆蓋下沉市場、從城市到鄉村的醫患教育體系,提供線上問診、疾病管理等數字化醫療健康服務。
雙方並將通過創新的「互聯網+」模式,進行線上線下聯動的真實世界研究項目,協助後疫情時代下以患者為中心的變革性臨床研究項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.